Janux Therapeutics, Inc. (JANX) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
JANX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
JANX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -1576.7% | -1576.7% |
| 2024 | 80.5% | -933.6% | -651.6% |
| 2023 | 75.8% | -902.9% | -721.2% |
| 2022 | 90.2% | -779.0% | -732.2% |
| 2021 | 100.0% | -905.4% | -898.3% |
Download Data
Export JANX earnings history in CSV or JSON format
Free sign-in required to download data
Janux Therapeutics, Inc. (JANX) Earnings Overview
As of May 8, 2026, Janux Therapeutics, Inc. (JANX) reported trailing twelve-month net income of -$158M, reflecting -43.0% year-over-year growth. The company earned $-2.54 per diluted share over the past four quarters, with a net profit margin of -1576.7%.
Looking at the long-term picture, JANX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 2019.
Janux Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), KYMR (-$315M net income, -794.4% margin), RCUS (-$369M net income, -142.9% margin), JANX has comparable earnings metrics. Compare JANX vs IMVT →
JANX Earnings vs Peers
Earnings metrics vs comparable public companies
JANX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$158M | -128.5% | -$158M | $-1.83 | -1576.7% | -1576.7% |
| 2024 | -$69M | -18.4% | -$99M | $-1.28 | -651.6% | -933.6% |
| 2023 | -$58M | +7.6% | -$73M | $-1.32 | -721.2% | -902.9% |
| 2022 | -$63M | -93.0% | -$67M | $-1.52 | -732.2% | -779.0% |
| 2021 | -$33M | -381.6% | -$33M | $-0.79 | -898.3% | -905.4% |
| 2020 | -$7M | -60.1% | -$5M | $-0.16 | - | - |
| 2019 | -$4M | - | -$4M | $-0.10 | - | - |
See JANX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JANX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare JANX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonJANX — Frequently Asked Questions
Quick answers to the most common questions about buying JANX stock.
Is JANX growing earnings?
JANX EPS fell to $-2.54, with earnings declining -43.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-158M.
What are JANX's profit margins?
Janux Therapeutics, Inc. net margin is -1576.7%, with operating margin at -1576.7%. Below-average margins reflect competitive or cost pressures.
How consistent are JANX's earnings?
JANX earnings data spans 2019-2025. The declining earnings trend is -43.0% YoY. Historical data enables comparison across business cycles.